$0.6833
-0.0162-2.32%
Last update: Nov 4, 4:16 PM
Cognition Therapeutics Inc (CGTX) Stock Price, Quote, News & History
CGTXNASDAQ
Cognition Therapeutics shares rose 30% pre-market after the FDA confirmed its Phase 3 trial for Alzheimer's drug Zervimesine.
You can purchase shares of Cognition Therapeutics (NASDAQ:CGTX) through any online brokerage.
Other companies in Cognition Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Cognition Therapeutics has a consensus price target of $5.75.
The stock price for Cognition Therapeutics (NASDAQ: CGTX) is $0.6969 last updated November 4, 2026 at 4:16 PM EST.
There are no upcoming dividends for Cognition Therapeutics.
Cognition Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Cognition Therapeutics.
Cognition Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina....
